AbbVie (ABBV)
(Delayed Data from NYSE)
$201.68 USD
+1.21 (0.60%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$201.68 USD
+1.21 (0.60%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $110.26 in the latest trading session, marking a +1.89% move from the prior day.
The Zacks Analyst Blog Highlights: Netflix, Toyota, AbbVie, Merck and Sinopec
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Toyota, AbbVie, Merck and Sinopec
Top Stock Reports for Netflix, Toyota & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Toyota Motor (TM), and AbbVie (ABBV).
Zacks Market Edge Highlights: AbbVie, Innovative Industrial Properties, Weyerhaeuser, Nutrien and Broadcom
by Zacks Equity Research
Zacks Market Edge Highlights: AbbVie, Innovative Industrial Properties, Weyerhaeuser, Nutrien and Broadcom
5 Innovative Companies That Will Pay You Cold Hard Cash
by Tracey Ryniec
Who says you have to own "boring" utilities, insurers and telecoms to get big dividends?
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
5 Stocks to Watch Amid Continued Expansion in the Biotech Industry
by Kaustav Ghosh
The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)
Why Is AbbVie (ABBV) Down 2.7% Since Last Earnings Report?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA
by Zacks Equity Research
Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.
Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout
by Kinjel Shah
Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion
Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.
2 Large Cap Stocks to Buy for Income and Growth Amid Tech Volatility
by Benjamin Rains
Investors might want to add a few large cap names outside of the tech world that also provide income through solid dividend yields...
AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Ironwood (IRWD) Q4 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter. However, outlook for 2021 misses market expectations.
3 Great Blue Chip Dividend Stocks to Buy Now with Dow at Records
by Benjamin Rains
Investors should always be on the lookout for ways to diversify and bolster their portfolios. One great place to start is with large cap stocks that pay solid dividends...
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.
Pharma Stock Roundup: AZN's Q4 Earnings, FDA Approval for LLY & SNY's Drugs
by Kinjel Shah
AstraZeneca (AZN) announces Q4 results. FDA approves Lilly's COVID-19 antibody cocktail & Sanofi's (SNY) Libtayo for a new indication.
AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod
by Zacks Equity Research
AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients.
Sanofi (SNY)/Regeneron's Libtayo Gets FDA Nod for 2nd Indication
by Zacks Equity Research
The FDA approves Sanofi (SNY)/Regeneron's Libtayo for treating patients with advanced/metastatic basal cell carcinoma. The is the second approved indication for the drug in the United States.
The Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Caterpillar, Deere & Co and MetLife
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Caterpillar, Deere & Co and MetLife
Q4 Earnings Season Scorecard and Analyst Reports for Exxon, AbbVie & Caterpillar
by Sheraz Mian
We have provided a real-time update on the Q4 earnings season in today's Research Daily, in addition to featuring new research reports on Exxon (XOM), AbbVie (ABBV) and Caterpillar (CAT).
Here is Why Growth Investors Should Buy AbbVie (ABBV) Now
by Zacks Equity Research
AbbVie (ABBV) could produce exceptional returns because of its solid growth attributes.
What Makes AbbVie (ABBV) a New Buy Stock
by Zacks Equity Research
AbbVie (ABBV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ABBV or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ABBV vs. LLY: Which Stock Is the Better Value Option?